<DOC>
	<DOC>NCT00042588</DOC>
	<brief_summary>The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Current diagnosis of communityacquired pneumonia. Evidence of systemic inflammatory response to infection. Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator. Presence of organ failure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>Safety and Efficacy</keyword>
	<keyword>Community-Acquired Pneumonia, Sepsis</keyword>
</DOC>